Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Program for Inhaled Aztreonam Lysine in Cystic Fibrosis Patients with Pseudomonas Aeruginosa Infection
2015-000396-26Phase 4
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aztreonam in cystic fibrosis (CF) and Pseudomonal infection, sponsored by Gilead Sciences. Primary endpoint: Expanded access to aztreonam lysine for inhalation.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2015-000396-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000396-26.